male sexual problems
National Institutes of Health Consensus Development
Impotence Conference Statement
December 7-9, 1992
CONTENTS:
ABSTRACT
INTRODUCTION
Prevalence and Association of
Erectile Dysfunction with Age.
Clinical, Psychological, and
Social Impact of Erectile Dysfunction.
Physiology of Erection.
Erectile Dysfunction.
Risk
Factors of Erectile Dysfunction.
Prevention of Erectile Dysfunction.
Diagnosis of Erectile Dysfunction.
Treatments for Erectile Dysfunction.
Psychotherapy and Behavioral
Therapy for Erectile Dysfunction.
Medical Therapy for Erectile Dysfunction.
Intracavernosal Injection Therapy for
Erectile Dysfunction.
Vacuum/Constrictive Devices to Treat
Erectile Dysfunction
Vascular Surgery to Treat Erectile
Dysfunction.
Penile Prostheses to Treat Erectile
Dysfunction.
Staging of Erectile Dysfunction
Treatment
Improving Knowledge of Erectile
Dysfunction.
Strategies for Improving
Public Knowledge of Erectile Dysfunction.
Strategies for
Improving Professional Knowledge of Erectile Dysfunction.
What are the needs for
future erectile dysfunction research?
CONCLUSIONS
CONSENSUS
DEVELOPMENT PANEL
ABSTRACT
The National Institutes of Health Consensus Development Conference on
Impotence was convened to address (1) the prevalence and clinical,
psychological, and social impact of erectile dysfunction; (2) the risk factors
for erectile dysfunction and how they might be used in preventing its
development; (3) the need for and appropriate diagnostic assessment and
evaluation of patients with erectile dysfunction; (4) the efficacies and risks
of behavioral, pharmacological, surgical, and other treatments for erectile
dysfunction; (5) strategies for improving public and professional awareness and
knowledge of erectile dysfunction; and (6) future directions for research in
prevention, diagnosis, and management of erectile dysfunction. Following 2 days
of presentations by experts and discussion by the audience, a consensus panel
weighed the evidence and prepared their consensus statement.
Among their findings, the panel concluded that
(1) the term "erectile dysfunction" should replace the term
"impotence"; (2) the likelihood of erectile dysfunction increases
with age but is not an inevitable consequence of aging; (3) embarrassment of
patients and reluctance of both patients and health care providers to discuss
sexual matters candidly contribute to underdiagnosis of erectile dysfunction;
(4) many cases of erectile dysfunction can be successfully managed with
appropriately selected therapy; (5) the diagnosis and treatment of erectile
dysfunction must be specific and responsive to the individual patient's needs
and that compliance as well as the desires and expectations of both the patient
and partner are important considerations in selecting appropriate therapy; (6)
education of health care providers and the public on aspects of human
sexuality, sexual dysfunction, and the availability of successful treatments is
essential; and (7) erectile dysfunction is an important public health problem
deserving of increased support for basic science investigation and applied
research.
The full text of the consensus panel's
statement follows.
The term "impotence," as applied to the title of this
conference, has traditionally been used to signify the inability of the male to
attain and maintain erection of the penis sufficient to permit satisfactory
sexual intercourse. However, this use has often led to confusing and
uninterpretable results in both clinical and basic science investigations.
This, together with its pejorative implications, suggests that the more precise
term "erectile dysfunction" be used instead to signify an inability
of the male to achieve an erect penis as part of the overall multifaceted
process of male sexual function.
This process comprises a variety of physical
aspects with important psychological and behavioral overtones. In analyzing the
material presented and discussed at this conference, this consensus statement
addresses issues of male erectile dysfunction, as implied by the term
"impotence." However, it should be recognized that desire, orgasmic
capability, and ejaculatory capacity may be intact even in the presence of
erectile dysfunction or may be deficient to some extent and contribute to the
sense of inadequate sexual function.
Erectile dysfunction affects
millions of men. Although for some men erectile function may not be the best or
most important measure of sexual satisfaction, for many men erectile
dysfunction creates mental stress that affects their interactions with family
and associates. Many advances have occurred in both diagnosis and treatment of
erectile dysfunction. However, its various aspects remain poorly understood by
the general population and by most health care professionals. Lack of a simple
definition, failure to delineate precisely the problem being assessed, and the
absence of guidelines and parameters to determine assessment and treatment
outcome and long-term results, have contributed to this state of affairs by
producing misunderstanding, confusion, and ongoing concern. That results have
not been communicated effectively to the public has compounded this
situation.
Cause-specific assessment and treatment of male
sexual dysfunction will require recognition by the public and the medical
community that erectile dysfunction is a part of overall male sexual
dysfunction. The multifactorial nature of erectile dysfunction, comprising both
organic and psychologic aspects, may often require a multidisciplinary approach
to its assessment and treatment. This consensus report addresses these issues,
not only as isolated health problems but also in the context of societal and
individual perceptions and expectations.
Erectile dysfunction is often assumed to be a
natural concomitant of the aging process, to be tolerated along with other
conditions associated with aging. This assumption may not be entirely correct.
For the elderly and for others, erectile dysfunction may occur as a consequence
of specific illnesses or of medical treatment for certain illnesses, resulting
in fear, loss of image and self-confidence, and depression.
For example, many men with diabetes mellitus
may develop erectile dysfunction during their young and middle adult years.
Physicians, diabetes educators, and patients and their families are sometimes
unaware of this potential complication. Whatever the causal factors, discomfort
of patients and health care providers in discussing sexual issues becomes a
barrier to pursuing treatment.
Erectile dysfunction can be effectively treated
with a variety of methods. Many patients and health care providers are unaware
of these treatments, and the dysfunction thus often remains untreated,
compounded by its psychological impact. Concurrent with the increase in the
availability of effective treatment methods has been increased availability of
new diagnostic procedures that may help in the selection of an effective,
cause-specific treatment. This conference was designed to explore these issues
and to define the state of the art.
To examine what is known about the
demographics, etiology, risk factors, pathophysiology, diagnostic assessment,
treatments (both generic and cause-specific), and the understanding of their
consequences by the public and the medical community, the National Institute of
Diabetes and Digestive and Kidney Diseases and the Office of Medical
Applications of Research of the National Institutes of Health, in conjunction
with the National Institute of Neurological Disorders and Stroke and the
National Institute on Aging, convened a consensus development conference on
male impotence on December 7-9, 1992. After 1 1/2 days of presentations by
experts in the relevant fields involved with male sexual dysfunction and
erectile impotence or dysfunction, a consensus panel comprised of
representatives from urology, geriatrics, medicine, endocrinology, psychiatry,
psychology, nursing, epidemiology, biostatistics, basic sciences, and the
public considered the evidence and developed answers to the questions that
follow.
WHAT ARE THE
PREVALENCE AND CLINICAL, PSYCHOLOGICAL, AND SOCIAL IMPACT OF IMPOTENCE
(CULTURAL, GEOGRAPHICAL, NATIONAL, ETHNIC, RACIAL, MALE/FEMALE PERCEPTIONS AND
INFLUENCES)?
Estimates of the prevalence of impotence depend on the definition
employed for this condition. For the purposes of this consensus development
conference statement, impotence is defined as male erectile dysfunction, that
is, the inability to achieve or maintain an erection sufficient for
satisfactory sexual performance. Erectile performance has been characterized by
the degree of dysfunction, and estimates of prevalence (the number of men with
the condition) vary depending on the definition of erectile dysfunction
used.
Appallingly little is known about the
prevalence of erectile dysfunction in the United States and how this prevalence
varies according to individual characteristics (age, race, ethnicity,
socioeconomic status, and concomitant diseases and conditions). Data on
erectile dysfunction available from the 1940's applied to the present U.S. male
population produce an estimate of erectile dysfunction prevalence of 7
million.
More recent estimates suggest that the number
of U.S. men with erectile dysfunction may more likely be near 10-20 million.
Inclusion of individuals with partial erectile dysfunction increases the
estimate to about 30 million. The majority of these individuals will be older
than 65 years of age. The prevalence of erectile dysfunction has been found to
be associated with age. A prevalence of about 5 percent is observed at age 40,
increasing to 15-25 percent at age 65 and older. One-third of older men
receiving medical care at a Department of Veterans' Affairs ambulatory clinic
admitted to problems with erectile function.
Causes contributing to erectile dysfunction can
be broadly classified into two categories: organic and psychologic. In reality,
while the majority of patients with erectile dysfunction are thought to
demonstrate an organic component, psychological aspects of self-confidence,
anxiety, and partner communication and conflict are often important
contributing factors.
The 1985 National Ambulatory Medical Care
Survey indicated that there were about 525,000 visits for erectile dysfunction,
accounting for 0.2 percent of all male ambulatory care visits. Estimates of
visits per 1,000 population increased from about 1.5 for the age group 25-34 to
15.0 for those age 65 and above. The 1985 National Hospital Discharge Survey
estimated that more than 30,000 hospital admissions were for erectile
dysfunction.
Geographic, Racial, Ethnic, Socioeconomic, and Cultural Variation in
Erectile Dysfunction. Very little is known about variations in prevalence of
erectile dysfunction across geographic, racial, ethnic, socioeconomic, and
cultural groups. Anecdotal evidence points to the existence of racial, ethnic,
and other cultural diversity in the perceptions and expectation levels for
satisfactory sexual functioning. These differences would be expected to be
reflected in these groups' reaction to erectile dysfunction, although few data
on this issue appear to exist.
One report from a recent community survey
concluded that erectile failure was the leading complaint of males attending
sex therapy clinics. Other studies have shown that erectile disorders are the
primary concern of sex therapy patients in treatment. This is consistent with
the view that erectile dysfunction may be associated with depression, loss of
self-esteem, poor self-image, increased anxiety or tension with one's sexual
partner, and/or fear and anxiety associated with contracting sexually
transmitted diseases, including AIDS.
Male/Female Perceptions and Influences. The
diagnosis of erectile dysfunction may be understood as the presence of a
condition limiting choices for sexual interaction and possibly limiting
opportunity for sexual satisfaction. The impact of this condition depends very
much on the dynamics of the relationship of the individual and his sexual
partner and their expectation of performance. When changes in sexual function
are perceived by the individual and his partner as a natural consequence of the
aging process, they may modify their sexual behavior to accommodate the
condition and maintain sexual satisfaction. Increasingly, men do not perceive
erectile dysfunction as a normal part of aging and seek to identify means by
which they may return to their previous level and range of sexual activities.
Such levels and expectations and desires for future sexual interactions are
important aspects of the evaluation of patients presenting with a chief
complaint of erectile dysfunction.
In men of all ages, erectile failure may
diminish willingness to initiate sexual relationships because of fear of
inadequate sexual performance or rejection. Because males, especially older
males, are particularly sensitive to the social support of intimate
relationships, withdrawal from these relationships because of such fears may
have a negative effect on their overall health.
WHAT ARE THE
RISK FACTORS CONTRIBUTING TO IMPOTENCE? CAN THESE BE UTILIZED IN PREVENTING
DEVELOPMENT OF IMPOTENCE?
The male erectile response is a vascular event initiated by neuronal
action and maintained by a complex interplay between vascular and neurological
events. In its most common form, it is initiated by a central nervous system
event that integrates psychogenic stimuli (perception, desire, etc.) and
controls the sympathetic and parasympathetic innervation of the penis. Sensory
stimuli from the penis are important in continuing this process and in
initiating a reflex arc that may cause erection under proper circumstances and
may help to maintain erection during sexual activity.
Parasympathetic input allows erection by
relaxation of trabecular smooth muscle and dilation of the helicine arteries of
the penis. This leads to expansion of the lacunar spaces and entrapment of
blood by compressing venules against the tunica albuginea, a process referred
to as the corporal veno- occlusive mechanism. The tunica albuginea must have
sufficient stiffness to compress the venules penetrating it so that venous
outflow is blocked and sufficient tumescence and rigidity can occur.
Acetylcholine released by the parasympathetic
nerves is thought to act primarily on endothelial cells to release a second
nonadrenergic-noncholinergic carrier of the signal that relaxes the trabecular
smooth muscle. Nitric oxide released by the endothelial cells, and possibly
also of neural origin, is currently thought to be the leading of several
candidates as this nonadrenergic-noncholinergic transmitter; but this has not
yet been conclusively demonstrated to the exclusion of other potentially
important substances (e.g., vasoactive intestinal polypeptide). The relaxing
effect of nitric oxide on the trabecular smooth muscle may be mediated through
its stimulation of guanylate cyclase and the production of cyclic guanosine
monophosphate (cGMP), which would then function as a second messenger in this
system.
Constriction of the trabecular smooth muscle
and helicine arteries induced by sympathetic innervation makes the penis
flaccid, with blood pressure in the cavernosal sinuses of the penis near venous
pressure. Acetylcholine is thought to decrease sympathetic tone. This may be
important in a permissive sense for adequate trabecular smooth muscle
relaxation and consequent effective action of other mediators in achieving
sufficient inflow of blood into the lacunar spaces. When the trabecular smooth
muscle relaxes and helicine arteries dilate in response to parasympathetic
stimulation and decreased sympathetic tone, increased blood flow fills the
cavernous spaces, increasing the pressure within these spaces so that the penis
becomes erect. As the venules are compressed against the tunica albuginea,
penile pressure approaches arterial pressure, causing rigidity. Once this state
is achieved, arterial inflow is reduced to a level that matches venous
outflow.
Because adequate arterial supply is critical for erection, any
disorder that impairs blood flow may be implicated in the etiology of erectile
failure. Most of the medical disorders associated with erectile dysfunction
appear to affect the arterial system. Some disorders may interfere with the
corporal veno-occlusive mechanism and result in failure to trap blood within
the penis, or produce leakage such that an erection cannot be maintained or is
easily lost.
Damage to the autonomic pathways innervating
the penis may eliminate "psychogenic" erection initiated by the
central nervous system. Lesions of the somatic nervous pathways may impair
reflexogenic erections and may interrupt tactile sensation needed to maintain
psychogenic erections. Spinal cord lesions may produce varying degrees of
erectile failure depending on the location and completeness of the lesions. Not
only do traumatic lesions affect erectile ability, but disorders leading to
peripheral neuropathy may impair neuronal innervation of the penis or of the
sensory afferents. The endocrine system itself, particularly the production of
androgens, appears to play a role in regulating sexual interest, and may also
play a role in erectile function.
Psychological processes such as depression,
anxiety, and relationship problems can impair erectile functioning by reducing
erotic focus or otherwise reducing awareness of sensory experience. This may
lead to inability to initiate or maintain an erection. Etiologic factors for
erectile disorders may be categorized as neurogenic, vasculogenic, or
psychogenic, but they most commonly appear to derive from problems in all three
areas acting in concert.
Little is known about the natural history of erectile dysfunction.
This includes information on the age of onset, incidence rates stratified by
age, progression of the condition, and frequency of spontaneous recovery. There
also are very limited data on associated morbidity and functional impairment.
To date, the data are predominantly available for whites, with other racial and
ethnic populations represented only in smaller numbers that do not permit
analysis of these issues as a function of race or ethnicity.
Erectile dysfunction is clearly a symptom of
many conditions, and certain risk factors have been identified, some of which
may be amenable to prevention strategies. Diabetes mellitus, hypogonadism in
association with a number of endocrinologic conditions, hypertension, vascular
disease, high levels of blood cholesterol, low levels of high density
lipoprotein, drugs, neurogenic disorders, Peyronie's disease, priapism,
depression, alcohol ingestion, lack of sexual knowledge, poor sexual
techniques, inadequate interpersonal relationships or their deterioration, and
many chronic diseases, especially renal failure and dialysis, have been
demonstrated as risk factors. Vascular surgery is also often a risk factor. Age
appears to be a strong indirect risk factor in that it is associated with an
increased likelihood of direct risk factors. Other factors require more
extensive study. Smoking has an adverse effect on erectile function by
accentuating the effects of other risk factors such as vascular disease or
hypertension. To date, vasectomy has not been associated with an increased risk
of erectile dysfunction other than causing an occasional psychological reaction
that could then have a psychogenic influence. Accurate risk factor
identification and characterization are essential for concerted efforts at
prevention of erectile dysfunction.
Although erectile dysfunction increases progressively with age, it is
not an inevitable consequence of aging. Knowledge of the risk factors can guide
prevention strategies. Specific antihypertensive, antidepressant, and
antipsychotic drugs can be chosen to lessen the risk of erectile failure.
Published lists of prescription drugs that may impair erectile functioning
often are based on reports implicating a drug without systematic study. Such
studies are needed to confirm the validity of these suggested associations. In
the individual patient, the physician can modify the regimen in an effort to
resolve the erectile problem.
It is important that physicians and other
health care providers treating patients for chronic conditions periodically
inquire into the sexual functioning of their patients and be prepared to offer
counsel for those who experience erectile difficulties. Lack of sexual
knowledge and anxiety about sexual performance are common contributing factors
to erectile dysfunction. Education and reassurance may be helpful in preventing
the cascade into serious erectile failure in individuals who experience minor
erectile difficulty due to medications or common changes in erectile
functioning associated with chronic illnesses or with aging.
The appropriate evaluation of all men with
erectile dysfunction should include a medical and detailed sexual history
(including practices and techniques), a physical examination, a psycho-social
evaluation, and basic laboratory studies. When available, a multidisciplinary
approach to this evaluation may be desirable. In selected patients, further
physiologic or invasive studies may be indicated. A sensitive sexual history,
including expectations and motivations, should be obtained from the patient
(and sexual partner whenever possible) in an interview conducted by an
interested physician or another specially trained professional. A written
patient questionnaire may be helpful but is not a substitute for the interview.
The sexual history is needed to accurately define the patient's specific
complaint and to distinguish between true erectile dysfunction, changes in
sexual desire, and orgasmic or ejaculatory disturbances. The patient should be
asked specifically about perceptions of his erectile dysfunction, including the
nature of onset, frequency, quality, and duration of erections; the presence of
nocturnal or morning erections; and his ability to achieve sexual satisfaction.
Psychosocial factors related to erectile dysfunction should be probed,
including specific situational circumstances, performance anxiety, the nature
of sexual relationships, details of current sexual techniques, expectations,
motivation for treatment, and the presence of specific discord in the patient's
relationship with his sexual partner. The sexual partner's own expectations and
perceptions should also be sought since they may have important bearing on
diagnosis and treatment recommendations.
The general medical history is important in
identifying specific risk factors that may account for or contribute to the
patient's erectile dysfunction. These include vascular risk factors such as
hypertension, diabetes, smoking, coronary artery disease, peripheral vascular
disorders, pelvic trauma or surgery, and blood lipid abnormalities. Decreased
sexual desire or history suggesting a hypogonadal state could indicate a
primary endocrine disorder. Neurologic causes may include a history of diabetes
mellitus or alcoholism with associated peripheral neuropathy. Neurologic
disorders such as multiple sclerosis, spinal injury, or cerebrovascular
accidents are often obvious or well defined prior to presentation. It is
essential to obtain a detailed medication and illicit drug history since an
estimated 25 percent of cases of erectile dysfunction may be attributable to
medications for other conditions. Past medical history can reveal important
causes of erectile dysfunction, including radical pelvic surgery, radiation
therapy, Peyronie's disease, penile or pelvic trauma, prostatitis, priapism, or
voiding dysfunction. Information regarding prior evaluation or treatment for
"impotence" should be obtained. A detailed sexual history, including
current sexual techniques, is important in the general history obtained. It is
also important to determine if there have been previous psychiatric illnesses
such as depression or neuroses.
Physical examination should include the
assessment of male secondary sex characteristics, femoral and lower extremity
pulses, and a focused neurologic examination including perianal sensation, anal
sphincter tone, and bulbocavernosus reflex. More extensive neurologic tests,
including dorsal nerve conduction latencies, evoked potential measurements, and
corpora cavernosal electromyography lack normative (control) data and appear at
this time to be of limited clinical value. Examination of the genitalia
includes evaluation of testis size and consistency, palpation of the shaft of
the penis to determine the presence of Peyronie's plaques, and a digital rectal
examination of the prostate with assessment of anal sphincter tone.
Endocrine evaluation consisting of a morning
serum testosterone is generally indicated. Measurement of serum prolactin may
be indicated. A low testosterone level merits repeat measurement together with
assessment of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and
prolactin levels. Other tests may be helpful in excluding unrecognized systemic
disease and include a complete blood count, urinalysis, creatinine, lipid
profile, fasting blood sugar, and thyroid function studies.
Although not indicated for routine use,
nocturnal penile tumescence (NPT) testing may be useful in the patient who
reports a complete absence of erections (exclusive of nocturnal
"sleep" erections) or when a primary psychogenic etiology is
suspected. Such testing should be performed by those with expertise and
knowledge of its interpretation, pitfalls, and usefulness. Various methods and
devices are available for the evaluation of nocturnal penile tumescence, but
their clinical usefulness is restricted by limitations of diagnostic accuracy
and availability of normative data. Further study regarding standardization of
NPT testing and its general applicability is indicated.
After the history, physical examination, and
laboratory testing, a clinical impression can be obtained of a primarily
psychogenic, organic, or mixed etiology for erectile dysfunction. Patients with
primary or associated psychogenic factors may be offered further psychologic
evaluation, and patients with endocrine abnormalities may be referred to an
endocrinologist to evaluate the possibility of a pituitary lesion or
hypogonadism. Unless previously diagnosed, suspicion of neurologic deficit may
be further assessed by complete neurologic evaluation. No further diagnostic
tests appear necessary for those patients who favor noninvasive treatment
(e.g., vacuum constrictive devices, or pharmacologic injection therapy).
Patients who do not respond satisfactorily to these noninvasive treatments may
be candidates for penile implant surgery or further diagnostic testing for
possible additional invasive therapies.
A rigid or nearly rigid erectile response to
intracavernous injection of pharmacologic test doses of a vasodilating agent
(see below) indicates adequate arterial and veno-occlusive function. This
suggests that the patient may be a suitable candidate for a trial of penile
injection therapy. Genital stimulation may be of use in increasing the erectile
response in this setting. This diagnostic technique also may be used to
differentiate a vascular from a primarily neuropathic or psychogenic etiology.
Patients who have an inadequate response to intracavernous pharmacologic
injection may be candidates for further vascular testing. It should be
recognized, however, that failure to respond adequately may not indicate
vascular insufficiency but can be caused by patient anxiety or discomfort. The
number of patients who may benefit from more extensive vascular testing is
small, but includes young men with a history of significant perineal or pelvic
trauma, who may have anatomic arterial blockage (either alone or with
neurologic deficit) to account for erectile dysfunction.
Studies to further define vasculogenic
disorders include pharmacologic duplex grey scale/color ultrasonography,
pharmacologic dynamic infusion cavernosometry/ cavernosography, and
pharmacologic pelvic/penile angiography. Cavernosometry, duplex
ultrasonography, and angiography performed either alone or in conjunction with
intracavernous pharmacologic injection of vasodilator agents rely on complete
arterial and cavernosal smooth muscle relaxation to evaluate arterial and
veno-occlusive function. The clinical effectiveness of these invasive studies
is severely limited by several factors, including the lack of normative data,
operator dependence, variable interpretation of results, and poor
predictability of therapeutic outcomes of arterial and venous surgery. At the
present time these studies might best be done in referral centers with specific
expertise and interest in investigation of the vascular aspects of erectile
dysfunction. Further clinical research is necessary to standardize methodology
and interpretation, to obtain control data on normals (as stratified according
to age), and to define what constitutes normality in order to assess the value
of these tests in their diagnostic accuracy and in their ability to predict
treatment outcome in men with erectile dysfunction.
Because of the difficulty in defining the clinical entity of erectile
dysfunction, there have been a variety of entry criteria for patients in
therapeutic trials. Similarly, the ability to assess efficacy of therapeutic
interventions is impaired by the lack of clear and quantifiable criteria of
erectile dysfunction. General considerations for treatment follow:
- Psychotherapy and/or behavioral therapy may be useful
for some patients with erectile dysfunction without obvious organic cause, and
for their partners. These may also be used as an adjunct to other therapies
directed at the treatment of organic erectile dysfunction. Outcome data from
such therapy, however, have not been well-documented or quantified, and
additional studies along these lines are indicated.
- Efficacy of therapy may be best achieved by inclusion of
both partners in treatment plans.
- Treatment should be individualized to the patient's
desires and expectations.
- Even though there are several effective treatments
currently available, long-term efficacy is in general relatively low. Moreover,
there is a high rate of voluntary cessation of treatment for all currently
popular forms of therapy for erectile dysfunction. Better understanding of the
reasons for each of these phenomena is needed.
Psychosocial factors are important in all forms of erectile
dysfunction. Careful attention to these issues and attempts to relieve sexual
anxieties should be a part of the therapeutic intervention for all patients
with erectile dysfunction. Psychotherapy and/or behavioral therapy alone may be
helpful for some patients in whom no organic cause of erectile dysfunction is
detected. Patients who refuse medical and surgical interventions also may be
helped by such counseling. After appropriate evaluation to detect and treat
coexistent problems such as issues related to the loss of a partner,
dysfunctional relationships, psychotic disorders, or alcohol and drug abuse,
psychological treatment focuses on decreasing performance anxiety and
distractions and on increasing a couple's intimacy and ability to communicate
about sex. Education concerning the factors that create normal sexual response
and erectile dysfunction can help a couple cope with sexual difficulties.
Working with the sexual partner is useful in improving the outcome of therapy.
Psychotherapy and behavioral therapy have been reported to relieve depression
and anxiety as well as to improve sexual function. However, outcome data of
psychological and behavioral therapy have not been quantified, and evaluation
of the success of specific techniques used in these treatments is poorly
documented. Studies to validate their efficacy are therefore strongly
indicated.
An initial approach to medical therapy should consider reversible
medical problems that may contribute to erectile dysfunction. Included in this
should be assessment of the possibility of medication-induced erectile
dysfunction with consideration for reduction of polypharmacy and/or
substitution of medications with lower probability of inducing erectile
dysfunction.
For some patients with an established diagnosis
of testicular failure (hypogonadism), androgen replacement therapy may
sometimes be effective in improving erectile function. A trial of androgen
replacement may be worthwhile in men with low serum testosterone levels if
there are no other contraindications. In contrast, for men who have normal
testosterone levels, androgen therapy is inappropriate and may carry
significant health risks, especially in the situation of unrecognized prostate
cancer. If androgen therapy is indicated, it should be given in the form of
intramuscular injections of testosterone enanthate or cypionate. Oral
androgens, as currently available, are not indicated. For men with
hyperprolactinemia, bromocriptine therapy often is effective in normalizing the
prolactin level and improving sexual function. A wide variety of other
substances taken either orally or topically have been suggested to be effective
in treating erectile dysfunction. Most of these have not been subjected to
rigorous clinical studies and are not approved for this use by the Food and
Drug Administration (FDA). Their use should therefore be discouraged until
further evidence in support of their efficacy and indicative of their safety is
available.
Injection of vasodilator substances into the corpora of the penis has
provided a new therapeutic technique for a variety of causes of erectile
dysfunction. The most effective and well-studied agents are papaverine,
phentolamine, and prostaglandin E[sub 1]. These have been used either singly or
in combination. Use of these agents occasionally causes priapism
(inappropriately persistent erections). This appears to have been seen most
commonly with papaverine. Priapism is treated with adrenergic agents, which can
cause life-threatening hypertension in patients receiving monoamine oxidase
inhibitors. Use of the penile vasodilators also can be problematic in patients
who cannot tolerate transient hypotension, those with severe psychiatric
disease, those with poor manual dexterity, those with poor vision, and those
receiving anticoagulant therapy. Liver function tests should be obtained in
those being treated with papaverine alone. Prostaglandin E[sub 1] can be used
together with papaverine and phentolamine to decrease the incidence of side
effects such as pain, penile corporal fibrosis, fibrotic nodules, hypotension,
and priapism. Further study of the efficacy of multitherapy versus monotherapy
and of the relative complications and safety of each approach is indicated.
Although these agents have not received FDA approval for this indication, they
are in widespread clinical use. Patients treated with these agents should give
full informed consent. There is a high rate of patient dropout, often early in
the treatment. Whether this is related to side effects, lack of spontaneity in
sexual relations, or general loss of interest is unclear. Patient education and
followup support might improve compliance and lessen the dropout rate. However,
the reasons for the high dropout rate need to be determined and
quantified.
Vacuum constriction devices may be effective at generating and
maintaining erections in many patients with erectile dysfunction and these
appear to have a low incidence of side effects. As with intracavernosal
injection therapy, there is a significant rate of patient dropout with these
devices, and the reasons for this phenomenon are unclear. The devices are
difficult for some patients to use, and this is especially so in those with
impaired manual dexterity. Also, these devices may impair ejaculation, which
can then cause some discomfort. Patients and their partners sometimes are
bothered by the lack of spontaneity in sexual relations that may occur with
this procedure. The patient is sometimes also bothered by the general
discomfort that can occur while using these devices. Partner involvement in
training with these devices may be important for successful outcome, especially
in regard to establishing a mutually satisfying level of sexual
activity.
Surgery of the penile venous system, generally involving venous
ligation, has been reported to be effective in patients who have been
demonstrated to have venous leakage. However, the tests necessary to establish
this diagnosis have been incompletely validated; therefore, it is difficult to
select patients who will have a predictably good outcome. Moreover, decreased
effectiveness of this approach has been reported as longer term followups have
been obtained. This has tempered enthusiasm for these procedures, which are
probably therefore best done in an investigational setting in medical centers
by surgeons experienced in these procedures and their evaluation.
Arterial revascularization procedures have a
very limited role (e.g., in congenital or traumatic vascular abnormality) and
probably should be restricted to the clinical investigation setting in medical
centers with experienced personnel. All patients who are considered for
vascular surgical therapy need to have appropriate preoperative evaluation,
which may include dynamic infusion pharmaco-cavernosometry and cavernosography
(DICC), duplex ultrasonography, and possibly arteriography. The indications for
and interpretations of these diagnostic procedures are incompletely
standardized; therefore, difficulties persist with using these techniques to
predict and assess the success of surgical therapy, and further investigation
to clarify their value and role in this regard is indicated.
Three forms of penile prostheses are available for patients who fail
with or refuse other forms of therapy: semirigid, malleable, and inflatable.
The effectiveness, complications, and acceptability vary among the three types
of prostheses, with the main problems being mechanical failure, infection, and
erosions. Silicone particle shedding has been reported, including migration to
regional lymph nodes; however, no clinically identifiable problems have been
reported as a result of the silicone particles. There is a risk of the need for
reoperation with all devices. Although the inflatable prostheses may yield a
more physiologically natural appearance, they have had a higher rate of failure
requiring reoperation. Men with diabetes mellitus, spinal cord injuries, or
urinary tract infections have an increased risk of prosthesis-associated
infection. This form of treatment may not be appropriate in patients with
severe penile corporal fibrosis, or severe medical illness. Circumcision may be
required for patients with phimosis and balanitis.
The patient and partner must be well informed about all therapeutic
options including their effectiveness, possible complications, and costs. As a
general rule, the least invasive or dangerous procedures should be tried first.
Psychotherapy and behavioral treatments and sexual counseling alone or in
conjunction with other treatments may be used in all patients with erectile
dysfunction who are willing to use this form of treatment. In patients in whom
psychogenic erectile dysfunction is suspected, sexual counseling should be
offered first. Invasive therapy should not be the primary treatment of choice.
If history, physical, and screening endocrine evaluations are normal and
nonpsychogenic erectile dysfunction is suspected, either vacuum devices or
intracavernosal injection therapy can be offered after discussion with the
patient and his partner. These latter two therapies may also be useful when
combined with psychotherapy in those with psychogenic erectile dysfunction in
whom psychotherapy alone has failed. Since further diagnostic testing does not
reliably establish specific diagnoses or predict outcomes of therapy, vacuum
devices or intracavernosal injections often are applied to a broad spectrum of
etiologies of male erectile dysfunction.
The motivation and expectations of the patient
and his partner and education of both are critical in determining which therapy
is chosen and in optimizing its outcome. If single therapy is ineffective,
combining two or more forms of therapy may be useful. Penile prostheses should
be placed only after patients have been carefully screened and informed.
Vascular surgery should be undertaken only in the setting of clinical
investigation and extensive clinical experience. With any form of therapy for
erectile dysfunction, long-term followup by health professionals is required to
assist the patient and his partner with adjustment to the therapeutic
intervention. This is particularly true for intracavernosal injection and
vacuum constriction therapies. Followup should include continued patient
education and support in therapy, careful determination of reasons for
cessation of therapy if this occurs, and provision of other options if earlier
therapies are unsuccessful.
Despite the accumulation of a substantial body
of scientific information about erectile dysfunction, large segments of the
public -- as well as the health professions -- remain relatively uninformed, or
-- even worse -- misinformed, about much of what is known. This lack of
information, added to a pervasive reluctance of physicians to deal candidly
with sexual matters, has resulted in patients being denied the benefits of
treatment for their sexual concerns. Although they might wish doctors would ask
them questions about their sexual lives, patients, for their part, are too
often inhibited from initiating such discussions themselves. Improving both
public and professional knowledge about erectile dysfunction will serve to
remove those barriers and will foster more open communication and more
effective treatment of this condition.
To a significant degree, the public, particularly older men, is
conditioned to accept erectile dysfunction as a condition of progressive aging
for which little can be done. In addition, there is considerable inaccurate
public information regarding sexual function and dysfunction. Often, this is in
the form of advertisements in which enticing promises are made, and patients
then become even more demoralized when promised benefits fail to materialize.
Accurate information on sexual function and the management of dysfunction must
be provided to affected men and their partners. They also must be encouraged to
seek professional help, and providers must be aware of the embarrassment and/or
discouragement that may often be reasons why men with erectile dysfunction
avoid seeking appropriate treatment.
To reach the largest audience, communications
strategies should include informative and accurate newspaper and magazine
articles, radio and television programs, as well as special educational
programs in senior centers. Resources for accurate information regarding
diagnosis and treatment options also should include doctors' offices, unions,
fraternal and service groups, voluntary health organizations, State and local
health departments, and appropriate advocacy groups. Additionally, since sex
education courses in schools uniformly address erectile function, the concept
of erectile dysfunction can easily be communicated in these forums as
well.
- Provide wide distribution of this statement to
physicians and other health professionals whose work involves patient
contact.
- Define a balance between what specific information is
needed by the medical and general public and what is available, and identify
what treatments are available.
- Promote the introduction of courses in human sexuality
into the curricula of graduate schools for all health care professionals.
Because sexual well-being is an integral part of general health, emphasis
should be placed on the importance of obtaining a detailed sexual history as
part of every medical history.
- Encourage the inclusion of sessions on diagnosis and
management of erectile dysfunction in continuing medical education
courses.
- Emphasize the desirability for an interdisciplinary
approach to the diagnosis and treatment of erectile dysfunction. An integrated
medical and psychosocial effort with continuing contact with the patient and
partner may enhance their motivation and compliance with treatment during the
period of sexual rehabilitation.
- Encourage the inclusion of presentations on erectile
dysfunction at scientific meetings of appropriate medical specialty
associations, State and local medical societies, and similar organizations of
other health professions.
- Distribute scientific information on erectile
dysfunction to the news media (print, radio, and television) to support their
efforts to disseminate accurate information on this subject and to counteract
misleading news reports and false advertising claims.
- Promote public service announcements, lectures, and
panel discussions on both commercial and public radio and television on the
subject of erectile dysfunction.
This consensus development conference on male erectile dysfunction
has provided an overview of current knowledge on the prevalence, etiology,
pathophysiology, diagnosis, and management of this condition. The growing
individual and societal awareness and open acknowledgment of the problem have
led to increased interest and resultant explosion of knowledge in each of these
areas. Research on this condition has produced many controversies, which also
were expressed at this conference. Numerous questions were identified that may
serve as foci for future research directions. These will depend on the
development of precise agreement among investigators and clinicians in this
field on the definition of what constitutes erectile dysfunction, and what
factors in its multifaceted nature contribute to its expression. In addition,
further investigation of these issues will require collaborative efforts of
basic science investigators and clinicians from the spectrum of relevant
disciplines and the rigorous application of appropriate research principles in
designing studies to obtain further knowledge and to promote understanding of
the various aspects of this condition.
The needs and directions for future research
can be considered as follows:
- Development of a symptom score sheet to aid in the
standardization of patient assessment and treatment outcome.
- Development of a staging system that may permit
quantitative and qualitative classification of erectile dysfunction.
- Studies on perceptions and expectations associated with
racial, cultural, ethnic, and societal influences on what constitutes normal
male erectile function and how these same factors may be responsible for the
development and/or perception of male erectile dysfunction.
- Studies to define and characterize what is normal
erectile function, possibly as stratified by age.
- Additional basic research on the physiological and
biochemical mechanisms that may underlie the etiology, pathogenesis, and
response to treatment of the various forms of erectile dysfunction.
- Epidemiological studies directed at the prevalence of
male erectile dysfunction and its medical and psychological correlates,
particularly in the context of possible racial, ethnic, socioeconomic, and
cultural variability.
- Additional studies of the mechanisms by which risk
factors may produce erectile dysfunction.
- Studies of strategies to prevent male erectile
dysfunction.
- Randomized clinical trials assessing the effectiveness
of specific behavioral, mechanical, pharmacologic, and surgical treatments,
either alone or in combination.
- Studies on the specific effects of hormones (especially
androgens) on male sexual function; determination of the frequency of endocrine
causes of erectile dysfunction (e.g., hypogonadism and hyperprolactinemia) and
the rates of success of appropriate hormonal therapy.
- Longitudinal studies in well-specified populations;
evaluation of alternative approaches for the systematic assessment of men with
erectile dysfunction; cost-effectiveness studies of diagnostic and therapeutic
approaches; formal outcomes research of the various approaches to the
assessment and treatment of this condition.
- Social/psychological studies of the impact of erectile
dysfunction on subjects, their partners, and their interactions, and factors
associated with seeking care.
- Development of new therapies, including pharmacologic
agents, and with emphasis on oral agents, that may address the cause of male
erectile dysfunction with greater specificity.
- Long-term followup studies to assess treatment effects,
patient compliance, and late adverse effects.
- Studies to characterize the significance of erectile
function and dysfunction in women.
Last updated: 8/05
top ~ male sexual problems ~
female
sexual problems ~ table of
contents ~
send page to
friend
|